Sanara MedTech Announces Publication Of Peer-Reviewed Study Evaluating Economic And Clinical Value Of CellerateRX Surgical Powder In Journal Of Medical Economics

Study demonstrates cost savings and improved health outcomes associated with the use of CellerateRX® as an adjunct to the standard of care for high-risk spinal surgery patients, compared to the standard of care alone

FORT WORTH, TX, March 11, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, today announced the publication of a peer-reviewed study evaluating the economic and clinical value of CellerateRX® Surgical Powder ("CellerateRX") in the Journal of Medical Economics. The study estimated the cost-effectiveness of adding CellerateRX as an adjunct to the standard of care for reducing postoperative complications in high-risk spinal surgery patients.